TrialJournal of cancer research and clinical oncology2016

Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin).

Seung Tae Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.